The US Justice Department, as part of its record $3-billion settlement with GlaxoSmithKline, said the drugmaker employed ostensibly scientific meetings to expand the market for antidepressants Paxil and Wellbutrin.
CME providers may see a modest uptick in funding from the FDA’s new safety plan for extended-release and long-acting opioids but may be hard-pressed to attract physicians.
GlaxoSmithKline will pay $3 billion to settle charges that it promoted antidepressants Paxil and Wellbutrin for unindicated uses and withheld safety data on diabetes drug Avandia.